Ulisse Biomed S.p.A. (BIT: UBM)

Market Cap	21.13M
Revenue (ttm)	420.92K
Net Income (ttm)	-6.97M
Shares Out	22.24M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,000
Average Volume	25,850
Open	0.946
Previous Close	0.906
Day's Range	0.862 - 0.950
52-Week Range	0.724 - 1.840
Beta	0.64
RSI	61.85
Earnings Date	Jan 3, 2025

About Ulisse Biomed

Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 10
• Stock Exchange: Borsa Italiana
• Ticker Symbol: UBM

Financial Performance

In 2023, Ulisse Biomed's revenue was 66,208, a decrease of -52.17% compared to the previous year's 138,437. Losses were -4.80 million, 266.8% more than in 2022.